Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party

We investigated the incidence and outcome of anti-CD19 chimeric antigen receptor (CAR) T-cells-associated Common Terminology Criteria for Adverse Events (CTCAE) ≥grade 3 cytopenia. In the EBMT CAR-T registry, we identified 398 adult patients with large B-cell lymphoma who had been treated with CAR-T...

Descripción completa

Detalles Bibliográficos
Autores principales: Penack, Olaf, Peczynski, Christophe, Koenecke, Christian, Polge, Emmanuelle, Kuhnl, Andrea, Fegueux, Nathalie, Daskalakis, Michael, Kröger, Nicolaus, Dreger, Peter, Besley, Caroline, Schanz, Urs, Bloor, Adrian, Ganser, Arnold, Forcade, Edouard, Corral, Lucia López, Passweg, Jakob R, Novak, Urban, Moiseev, Ivan, Schoemans, Hélène, Basak, Grzegorz W, Chabannon, Christian, Sureda, Anna, Averbuch, Dina, Glass, Bertram, de la Camara, Rafael, Peric, Zinaida
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124318/
https://www.ncbi.nlm.nih.gov/pubmed/37072350
http://dx.doi.org/10.1136/jitc-2022-006406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124318/
https://www.ncbi.nlm.nih.gov/pubmed/37072350
http://dx.doi.org/10.1136/jitc-2022-006406

Ejemplares similares